trending Market Intelligence /marketintelligence/en/news-insights/trending/ib8qsutjltqjf5nxrhqymg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Sunovion files application for Parkinson's disease treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Sunovion files application for Parkinson's disease treatment

Sunovion Pharmaceuticals Inc. is seeking U.S. approval for its Parkinson's medicine APL-130277 which is also known as the apomorphine sublingual film.

The Marlborough, Mass.-based company's new drug application with the U.S. Food and Drug Administration is supported by a phase 3 study of the drug.

The study demonstrated that APL-130277, which works by mimicking the action of dopamine, was better than placebo in treating so-called OFF periods experienced by 40% to 60% of Parkinson's patients, resulting in tremors, stiffness or slow movement.